• Respiratory and thoracic cancers

Alecensa Generic Name & Formulations

General Description

Alectinib 150mg; caps.

Pharmacological Class

Kinase inhibitor.

How Supplied



Generic Availability


Alecensa Indications


Treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Alecensa Dosage and Administration


Swallow whole. Take with food. 600mg twice daily until disease progression or unacceptable toxicity. Severe hepatic impairment (Child-Pugh C): 450mg twice daily. Dose modifications for adverse reactions: see full labeling.


Not established.

Alecensa Contraindications

Not Applicable

Alecensa Boxed Warnings

Not Applicable

Alecensa Warnings/Precautions


Monitor liver function tests (eg, ALT, AST, total bilirubin) every 2 weeks for the first 3 months, then monthly and as clinically indicated; test more frequently if transaminase and bilirubin elevated; withhold, resume at reduced dose, or permanently discontinue based on severity. Evaluate if presence of worsening respiratory symptoms; withhold if ILD/pneumonitis diagnosed; permanently discontinue if no other cause identified. Withhold for Grade 3 renal toxicity until recovery to ≤1.5×ULN, then resume at reduced dose; permanently discontinue if Grade 4 occurs. Monitor HR, BP regularly. If non-life-threatening symptomatic bradycardia occurs, withhold until asymptomatic or HR ≥60bpm; permanently discontinue in case(s) of recurrence or life-threatening bradycardia if no contributing concomitant medication identified. Assess CPK every 2 weeks for the first month and as clinically indicated; withhold, resume, or reduce dose based on severity. Withhold if hemolytic anemia is suspected; consider resuming at reduced dose upon resolution or permanently discontinue if confirmed. Severe hepatic or renal impairment/ESRD. Embryo-fetal toxicity. Pregnancy: avoid. Use effective contraception during and for 1 week (females) or 3 months (males) after final dose. Nursing mothers: not recommended (during and for 1 week after final dose).

Alecensa Pharmacokinetics

See Literature

Alecensa Interactions


Increased bradycardia with concomitant antihypertensives or other drugs known to cause bradycardia.

Alecensa Adverse Reactions

Adverse Reactions

Fatigue, constipation, edema, myalgia, anemia; hepatotoxicity, ILD/pneumonitis, renal impairment, bradycardia, CPK elevation, hemolytic anemia.

Alecensa Clinical Trials

See Literature

Alecensa Note

Not Applicable

Alecensa Patient Counseling

See Literature